Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.

Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G, Clapp-Channing N, Lee KL, Moss AJ.

JAMA. 2013 Jan 2;309(1):55-62. doi: 10.1001/jama.2012.157182.

2.

Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(14):1-74. Epub 2005 Sep 1.

3.

Defibrillator implantations for primary prevention in the United States: Inappropriate care or inadequate documentation: Insights from the National Cardiovascular Data ICD Registry.

Kaiser DW, Tsai V, Heidenreich PA, Goldstein MK, Wang Y, Curtis J, Turakhia MP; National Cardiovascular Data Registry.

Heart Rhythm. 2015 Oct;12(10):2086-93. doi: 10.1016/j.hrthm.2015.05.010. Epub 2015 May 14.

4.

Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.

Khazanie P, Hellkamp AS, Fonarow GC, Bhatt DL, Masoudi FA, Anstrom KJ, Heidenreich PA, Yancy CW, Curtis LH, Hernandez AF, Peterson ED, Al-Khatib SM.

J Am Heart Assoc. 2015 Aug 6;4(8):e002061. doi: 10.1161/JAHA.115.002061.

5.

Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.

Pun PH, Hellkamp AS, Sanders GD, Middleton JP, Hammill SC, Al-Khalidi HR, Curtis LH, Fonarow GC, Al-Khatib SM.

Nephrol Dial Transplant. 2015 May;30(5):829-35. doi: 10.1093/ndt/gfu274. Epub 2014 Nov 17.

6.

Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria?

Daugherty SL, Peterson PN, Wang Y, Curtis JP, Heidenreich PA, Lindenfeld J, Vidaillet HJ, Masoudi FA; NCDR.

Am Heart J. 2009 Aug;158(2):224-9. doi: 10.1016/j.ahj.2009.05.018.

PMID:
19619698
7.

Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.

Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders G.

Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):179-86. doi: 10.1161/CIRCOUTCOMES.114.001306. Epub 2015 Feb 10.

8.

Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%.

Al-Khatib SM, Hellkamp AS, Fonarow GC, Mark DB, Curtis LH, Hernandez AF, Anstrom KJ, Peterson ED, Sanders GD, Al-Khalidi HR, Hammill BG, Heidenreich PA, Hammill SC.

JAMA. 2014 Jun 4;311(21):2209-15. doi: 10.1001/jama.2014.5310.

9.

Long-term follow-up of patients with indication for a implantable defibrillator for primary prevention of death.

Hadid C, Avellana P, Di Toro D, Gomez CF, Visser M, Prieto N.

Arq Bras Cardiol. 2008 May;90(5):311-5. English, Portuguese.

10.

Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention.

Peterson PN, Varosy PD, Heidenreich PA, Wang Y, Dewland TA, Curtis JP, Go AS, Greenlee RT, Magid DJ, Normand SL, Masoudi FA.

JAMA. 2013 May 15;309(19):2025-34. doi: 10.1001/jama.2013.4982.

11.

Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.

Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ, Shadman R, Anand I, Lund LH, Dahlström U, Sartipy U, Maggioni A, Swedberg K, O'Conner C, Levy WC.

J Am Coll Cardiol. 2017 May 30;69(21):2606-2618. doi: 10.1016/j.jacc.2017.03.568.

PMID:
28545633
12.

Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).

Chen J, Johnson G, Hellkamp AS, Anderson J, Mark DB, Lee KL, Bardy GH, Poole JE.

J Am Coll Cardiol. 2013 May 28;61(21):2161-8. doi: 10.1016/j.jacc.2013.02.046. Epub 2013 Mar 26.

13.

Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.

Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LY, Sanders GD.

JACC Heart Fail. 2014 Dec;2(6):623-9. doi: 10.1016/j.jchf.2014.06.007. Epub 2014 Oct 8.

14.
15.

Primary prevention implantable cardioverter-defibrillators and survival in older women.

Zeitler EP, Hellkamp AS, Fonarow GC, Hammill SC, Curtis LH, Hernandez AF, Al-Khalidi HR, Curtis JP, Heidenreich PA, Anstrom KJ, Peterson ED, Mark DB, Hammill BG, Sanders GD, Al-Khatib SM.

JACC Heart Fail. 2015 Feb;3(2):159-67. doi: 10.1016/j.jchf.2014.09.006. Epub 2014 Nov 5.

16.

Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study.

Proclemer A, Muser D, Campana A, Zoni-Berisso M, Zecchin M, Locatelli A, Brieda M, Gramegna L, Santarone M, Chiodi L, Mazzone P, Rebellato L, Facchin D.

Int J Cardiol. 2013 Sep 30;168(2):1416-21. doi: 10.1016/j.ijcard.2012.12.042. Epub 2012 Dec 31.

PMID:
23287697
17.

New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.

Friedman DJ, Al-Khatib SM, Zeitler EP, Han J, Bardy GH, Poole JE, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LYT, Sanders GD.

Am Heart J. 2017 Sep;191:21-29. doi: 10.1016/j.ahj.2017.06.002. Epub 2017 Jun 9. Review.

PMID:
28888266
18.

Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.

Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Hess PL, Inoue LY, Sanders GD.

Am J Kidney Dis. 2014 Jul;64(1):32-9. doi: 10.1053/j.ajkd.2013.12.009. Epub 2014 Feb 8.

19.

Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.

Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, Boehmer JP, Carlson MD, Frantz RP, McNulty SE, Rogers JG, Anderson J, Johnson GW, Walsh MN, Poole JE, Mark DB, Lee KL, Bardy GH.

Circulation. 2009 Dec 1;120(22):2170-6. doi: 10.1161/CIRCULATIONAHA.109.853689. Epub 2009 Nov 16. Erratum in: Circulation. 2010 Feb 16;121(6):e39.

20.

Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).

Fishbein DP, Hellkamp AS, Mark DB, Walsh MN, Poole JE, Anderson J, Johnson G, Lee KL, Bardy GH; SCD-HeFT Investigators.

J Am Coll Cardiol. 2014 Jun 17;63(23):2560-2568. doi: 10.1016/j.jacc.2014.02.602. Epub 2014 Apr 9.

Supplemental Content

Support Center